Search Within

Breast Medicine Service

Formats
  1. Journal Article (2194)
  2. Meeting Abstract (1678)
  3. Review (81)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (10)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4164)
  2. Solid Tumor Oncology Division (4164)
  3. Survivorship Research (2364)
  4. GSK Faculty (1514)
  5. Population Sciences Research Program (1363)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1141)

More Groups

People
  1. Clifford Hudis (905)
  2. Larry Norton (760)
  3. Mark Robson (682)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (113)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (131)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (753)
  3. Springer (332)
  4. Elsevier Inc. (326)
  5. Oxford University Press (279)
  6. Nature Publishing Group (275)

More Publishers

Results (4164)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer
    Meeting Abstract

    Mai, N.; Liu, B.; Safonov, A.; Shen, S.; Zelizer, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.; Modi, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase 1 trial of exercise as first-line therapy for hormone receptor (HR)–positive advanced breast cancer (TBCRC 054)
    Meeting Abstract

    Iyengar, N. M.; Lavery, J. A.; Carlson, A.; Castillo, V.; Lehman, S.; Michalski, M. G.; Harrison, J.; Braun, A.; Flores, J.; Chun, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns in HR+/HER2-metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations
    Meeting Abstract

    Teysir, J.; Shen, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer
    Meeting Abstract

    Ah-Reum An, J.; Jasper, J.; Cabel, L.; Yildirim, S. Y.; da Silva, E. M.; Patel, R. K.; LaBella, M.; Teysir, J.; Mai, N.; Safonov, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial
    Meeting Abstract

    Curigliano, G.; O'Shaughnessy, J.; Bidard, F. C.; Kim, S. B.; Tokunaga, E.; Aftimos, P. G.; Manich, C. S.; Carey, L. A.; Okera, M.; Melo, É.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)
    Meeting Abstract

    Turner, N. C.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; Shankar, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
    Meeting Abstract

    Oliveira, M.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Jhaveri, K. L.; Juric, D.; Kalinsky, K.; Krop, I. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment-related neutropenia as a predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
    Meeting Abstract

    Fanucci, K.; Dueck, A. C.; Mayer, E. L.; Martin, M.; Haddad, T. C.; Zdenkowski, N.; Steger, G. G.; Novik, Y.; Suga, J. M.; Lemieux, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2-early breast cancer (EBC) eligible for NATALEE
    Meeting Abstract

    Abdou, Y.; Reid, S. A.; Jhaveri, K. L.; Pegram, M. D.; Schlam, I.; Sparano, J. A.; Olumba, B. T.; Santarsiero, E. C.; Ganapathy, V.; Akdere, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Impact of initial chemotherapy dosing on subsequent dosing patterns and treatment completion in early-stage breast cancer
    Meeting Abstract

    Iglesias, M. J. M.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Doud, R. P.; Gallagher, G. B.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save